NCT07200908Phase 3Recruiting

A Trial Evaluating Brelovitug (BJT-778) vs Bulevirtide for the Treatment of Chronic Hepatitis Delta Infection (AZURE-2)

Study sponsor: Mirum Pharmaceuticals, Inc. · MIRM

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2027-06-30Estimated
Enrollment · participants172Estimated
Source updated2026-10-08Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.